Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.50 |
| ▸ | PTPRC | P08575 | 1/20 | 0.50 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.47 |
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.45 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.45 |
| ▸ | CSNK1G1 | Q9HCP0 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | FGR | P09769 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.37 |
| ▸ | MEN1 | O00255 | 5/20 | 0.37 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7222595 | 0.83 | ADORA2A (0.50) | ADORA2APTPRCPABPC1HSPA1ACSNK1A1 | |
| SCHEMBL194707 | 0.78 | ADORA2A (0.41) | ADORA2APTPRCPABPC1HSPA1ACSNK1A1 | |
| SCHEMBL2961474 | 0.74 | MAOA (0.56) | MAOADPP4ALDH1A1L3MBTL1KMT2A | |
| SCHEMBL64318 | 0.72 | ADORA2A (0.86) | ADORA2APTPRCPABPC1HSPA1ACSNK1A1 | |
| SCHEMBL29944895 | 0.72 | ADORA2A (0.86) | ADORA2APTPRCPABPC1HSPA1ACSNK1A1 | |
| SCHEMBL5866516 | 0.72 | ADORA2A (0.71) | ADORA2APTPRCPABPC1HSPA1ACSNK1A1 | |
| SCHEMBL21840830 | 0.72 | ADORA2A (0.78) | ADORA2APTPRCPABPC1HSPA1ACSNK1A1 | |
| SCHEMBL29714477 | 0.70 | MEN1 (0.50) | PTPRCMAOAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL112133 | 0.70 | MEN1 (0.50) | PTPRCMAOAALDH1A1L3MBTL1KMT2A | |
| Hydrochloric Acid SCHEMBL8643197 | 0.70 | ADORA2A (0.83) | ADORA2APTPRCPABPC1HSPA1ACSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1655301-B1 | CYCLIC BIOISOSTERS OF PURINE SYSTEM DERIVATIVES AND A PHARMACEUTICAL COMPOSITION BASED THEREON | ZHILOV VALERY KHAZHMURATOVICH (RU) | 2015-03-11 | — | — | EP | claimed |
| US-8592421-B2 | Cyclic bioisosters of purine system derivatives and a pharmaceutical composition based thereon | Zhilov, Valery Khazhmuratovich (RU) | 2013-11-26 | — | — | US | claimed |
| EP-2074998-B1 | Use of cyclic bioisosteres of purine system derivatives for the treatment of diseases caused by disorders of nitrergic and dopaminergic systems | ZHILOV VALERY KHAZHMURATOVICH (RU) | 2013-10-16 | — | — | EP | claimed |
| US-7776833-B2 | Use of cyclic bioisosters of purine system derivatives for treating diseases produced by disorders of niterergic and dopaminergic systems | Zhilov, Valery Khazhmuratovich (RU) | 2010-08-17 | — | — | US | claimed |
| EP-2074998-A2 | Use of cyclic bioisosteres of purine system derivatives for the treatment of diseases caused by disorders of nitrergic and dopaminergic systems | Zhilov, Valery Khazhmuratovich (RU) | 2009-07-01 | — | — | EP | claimed |
| US-20080194501-A1 | Cyclic Bioisosters of Derivatives of a Purine System and Pharmaceutical Composition Based Thereon | ZHILOV, VALERY KHAZHMURATOVICH (RU) | 2008-08-14 | — | — | US | claimed |
| US-7326690-B2 | Modulation of cell fates and activities by phthalazinediones | BACH PHARMA, INC. (US) | 2008-02-05 | — | — | US | claimed |
| US-20070142303-A1 | Modulation of cell fates and activities by phthalazinediones | BACH PHARMA, INC. (US) | 2007-06-21 | — | — | US | claimed |
| US-20070135636-A1 | Use of cyclic bioisosters of purine system derivatives for treating diseases produced by disorders of niterergic and dopaminergic systems | VALERY KHAZHMURATOVICH ZHILOV (RU) | 2007-06-14 | — | — | US | claimed |
| EP-1655301-A1 | CYCLIC BIOISOSTERS OF PURINE SYSTEM DERIVATIVES AND A PHARMACEUTICAL COMPOSITION BASED THEREON | Zhilov, Valery Khazhmuratovich (RU) | 2006-05-10 | — | — | EP | claimed |
| EP-1655028-A2 | USE OF CYCLIC BIOISOSTERES OF PURINE SYSTEM DERIVATIVES FOR THE TREATMENT OF DISEASES CAUSED BY DISORDERS OF NITRERGIC AND DOPAMINERGIC SYSTEMS | Zhilov, Valery Khazhmuratovich (RU) | 2006-05-10 | — | — | EP | claimed |
| US-20180153889-A1 | MODULATION OF CELL FATES AND ACTIVITIES BY PHTHALAZINEDIONES | BACH PHARMA, INC. | 2018-06-07 | — | — | US | disclosed |
| US-9968602-B2 | Modulation of cell fates and activities by phthalazinediones | BACH PHARMA, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9732043-B2 | Process for preparing 5-amino-2,3-dihydrophthalazine-1,4-dione monosodium salt | BACH PHARMA, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| EP-2393361-B1 | PHARMACEUTICAL GRADE PHTHALAZINEDIONES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BACH PHARMA INC (US) | 2016-12-07 | — | — | EP | disclosed |
| WO-2003014090-A1 | AMINO-PHTHALAZINONE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PHARMACIA ITALIA S.P.A. (IT) | 2003-02-20 | — | — | WO | disclosed |
| US-4334069-A | Chemiluminescent phthalhydrazide-labeled hapten conjugates | MILES LABORATORIES, INC. (US) | 1982-06-08 | — | — | US | disclosed |
| US-4297273-A | MEDICAL DIAGNOSIS; IMMUNOASSAY | MILES LABORATORIES, INC. (US) | 1981-10-27 | — | — | US | disclosed |
| US-4226993-A | INTERMEDIATES FOR CHEMILUMINESCENT LABELED CONJUGATES | MILES LABORATORIES, INC. (US) | 1980-10-07 | — | — | US | disclosed |
| US-4212805-A | INTERMEDIATES OF PHTHALHYDRAZIDE-LABELED CONJUGATES | MILES LABORATORIES, INC. (US) | 1980-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135636-A1 | Use of cyclic bioisosters of purine system derivatives for treating diseases produced by disorders of niterergic and dopaminergic systems | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885PTPRC 2476/4885PABPC1 2727/4885 |
| US-20180153889-A1 | MODULATION OF CELL FATES AND ACTIVITIES BY PHTHALAZINEDIONES | NFE2L2, GPX4, TXNRD2 | ADORA2A 4328/4885PTPRC 300/4885PABPC1 3052/4885 |
| US-20080194501-A1 | Cyclic Bioisosters of Derivatives of a Purine System and Pharmaceutical Composition Based Thereon | ADORA3, ADORA2A, ADORA2B | ADORA2A 2/4885PTPRC 2304/4885PABPC1 1636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.